Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics names CEO

Carsten Thiel joins the biopharma from Alexion

Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel.

Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new position.

Steven Rouhandeh, executive chairman of Abeona, said: “As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialisation to Abeona.

“In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead.”

Following a 25-year career in the biopharmaceutical industry, Thiel has held numerous roles for several biopharma’s including Amgen and Roche.

20th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics